Clinical Study

Implications of Identifying Additional Cerebral Metastases during Gamma Knife Radiosurgery

Table 1

Study population and treatment characteristics*.

TreatmentStudy cohort,
No additional mets,
≥1 additional mets,

Age, years
 Median58.757.558.80.783
 Range29.0–85.529.0–85.530.6–82.6
Sex
 Male47 (35)24 (30)23 (43)0.196
 Female86 (65)55 (70)31 (57)
Primary pathology
 Lung62 (47)37 (47)25 (46)1.000
 Breast27 (20)16 (20)11 (20)1.000
 Melanoma15 (11)6 (8)9 (17)0.161
 Renal12 (9)9 (11)3 (6)0.359
 Other17 (13)11 (14)6 (11)0.792
WBRT
  Pre-GK-SRS63 (47)34 (43)29 (54)0.289
  Post-GK-SRS16 (12)9 (11)7 (13)0.792
  Neither54 (41)36 (46)18 (33)0.208
Craniotomy
  Yes34 (26)23 (29)11 (20)0.314
  No98 (74)56 (71)43 (80)
Chemotherapy
  Yes130 (98)78 (99)52 (96)0.566
  No3 (2)1 (1)2 (4)
Time between scans, days31 (4–81)29 (4–81)37 (7–78)0.111
Number of metastases
 Pre-GK-SRS1 (1–10)1 (1–9)2 (1–10)<0.001
 GK-SRS2 (1–21)1 (1–9)4 (2–21)<0.001
Progressive systemic disease
 Yes69 (52)34 (43)35 (65)0.021
 No64 (48)45 (57)19 (35)

*Number of patients (%), unless otherwise specified.